排序方式: 共有29条查询结果,搜索用时 15 毫秒
1.
2.
Sebastian P. Mondaca MD Dazhi Liu PharmD BCOP Jessica R. Flynn Sandy Badson Stefan Hamaway BS Mrinal M. Gounder MD Danny N. Khalil MD PhD Alexander E. Drilon MD Bob T. Li MD MPH Komal L. Jhaveri MD Alison M. Schram MD Katherine E. Kargus RN Mary Kate Kasler DNP MSN Natalie M. Blauvelt Neil H. Segal MD PhD Marinela Capanu PhD Margaret K. Callahan MD PhD David M. Hyman MD Maya Gambarin-Gelwan MD James J. Harding MD 《Cancer》2020,126(22):4967-4974
3.
4.
Pallawi Torka MD Othman S. Akhtar MD Nishitha M. Reddy MD Bora E. Baysal MD PhD Angela Kader BA CCRP Adrienne Groman MS Jenna Nichols RN MS CCRC Cory Mavis BS MS Joseph D. Tario PhD AnneMarie W. Block PhD Sheila N. J. Sait PhD Paola Ghione MD Suchitra Sundaram MD Eugene R. Przespolewski PharmD BCOP Alice Mohr FNP-C MSN Ian Lund PA-C Jessica Kostrewa NP Kenneth McWhite PA Joseph DeMarco PA Michael Johnson DNP BSN NP RN Andrea Darrall NP Rosh-Neke Thomas-Talley FNP-BC Paul K. Wallace PhD Vishala Neppalli MD Alan Hutson PhD Francisco J. Hernandez-Ilizaliturri MD 《Cancer》2022,128(8):1595-1604
5.
6.
7.
Mays TA 《Current pain and headache reports》2001,5(3):227-236
Most patients who have been diagnosed with cancer will experience pain at some point during the course of their disease. Often, opioid analgesics are not enough to completely alleviate the patient's pain and the selection of appropriate adjunct analgesic agents is critical. This article reviews the mechanisms of action and analgesic effects of several classes of antidepressants to enable the clinician to select the appropriate agent for the patient. 相似文献
8.
9.
10.
L. Lee Dupuis MScPhm ACPR FCSHP Sabrina Boodhan BScPhm ACPR Mark Holdsworth PharmD BCOP Paula D. Robinson MD MSc Richard Hain MD Carol Portwine MD FRCPC PhD Erin O'Shaughnessy RN MScN CPHON Lillian Sung MD PhD 《Pediatric blood & cancer》2013,60(7):1073-1082
This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc. 相似文献